ABL Diagnostics wins court approval to acquire TEXCELL operations

ABL Diagnostics has been selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations, keeping the Genopole site in Évry-Courcouronnes open and transferring 29 employees. The deal expands ABL Diagnostics’ footprint in virology, biosafety and infectious diseases while supporting its partnership-driven strategy with Institut Pasteur.

Why it matters: - The acquisition gives ABL Diagnostics a larger foothold in virology, biosafety and infectious diseases. - The deal preserves activity at the Genopole site in Évry-Courcouronnes and keeps specialized scientific operations in place. - ABL Diagnostics is adding TEXCELL’s expertise, contracts and assets to its existing molecular diagnostics platform.

What happened: - The Évry Commercial Court selected ABL Diagnostics to acquire TEXCELL’s assets and business operations. - The decision follows an industrial plan designed to keep the business running, preserve scientific expertise and create synergies with ABL Diagnostics’ existing activities. - The transaction covers TEXCELL’s strategic assets and operations. - Commercial contracts tied to the acquisition will continue. - Operations will remain at the Genopole site in Évry-Courcouronnes. - The acquisition transfers 29 employees, including 23 permanent staff and 6 apprentices or trainees. - ABL Diagnostics will assume accrued employee rights for the transferred workers, valued at €91,829.24, subject to final adjustment.

The details: - TEXCELL emerged from the scientific ecosystem of Institut Pasteur. - TEXCELL brings expertise in viral safety, biosafety, genomic analysis, immunological monitoring and services for biotechnology and innovative therapies. - Publicly available information shows TEXCELL France generated about €5.4 million of revenue in 2024, compared with €6.2 million in 2023 and €7.5 million in 2022. - The project’s overall economic value is estimated at about €2.9 million. - The purchase price for assets is €225,000, including €165,000 for intangible assets and €60,000 for tangible assets. - Inventories are being acquired for a lump sum of €30,000 excluding VAT. - Security deposits will be reconstituted at about €100,000. - ABL Diagnostics will assume lease financing tied to operational equipment, including future lease installments of €531,792.74, subject to final adjustment. - The company plans an industrial and technological investment program of €930,000. - ABL Diagnostics estimates an additional €1 million in working capital needs to support development of the acquired activities. - The transaction is financed from the group’s available financial resources. - The accepted offer’s terms are set out in documents filed with the Évry Commercial Court. - ABL Diagnostics says the deal aligns with its recent strategic initiatives with Institut Pasteur, including the HPV RNA-Seq genotyping project. - TEXCELL’s expertise complements ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - The acquisition gives ABL Diagnostics an operational presence at Genopole Évry-Courcouronnes. - ABL Diagnostics plans to recruit about five additional employees to support scientific activities from TEXCELL. - The company intends to continue developing the acquired assets for biomedical research, biological quality control and molecular diagnostics. - Characterized virus banks, cell line collections, virology expertise and biosafety infrastructure may support future tool development.

Between the lines: - The deal is as much about scientific fit as scale, linking ABL Diagnostics more tightly to the Institut Pasteur ecosystem. - ABL Diagnostics is using external growth to deepen capabilities that complement its internal innovation strategy. - The retention of staff and site operations suggests the company wants continuity first, then gradual expansion.

What’s next: - ABL Diagnostics will provide more information after legal and administrative formalities are completed. - The company plans to explain how the acquired activities will fit into its strategic roadmap and 2026 objectives. - Management expects to invest in automation, infrastructure modernization, team expansion and broader scientific development if the integration proceeds as planned.

The bottom line: - ABL Diagnostics is turning a court-approved acquisition into a broader push in virology and infectious-disease services, with Genopole as a new operating base.